In 2016, the US Treasury Department instituted a new measure that put an end to the $ 160 billion mega-merger between Pfizer and
Irish specialty pharma Allergan, a deal that was pitched as a way to help Pfizer cut its tax bill by moving its corporate headquarters to Ireland.